Eteplirsen

2016's Most Hyped Events: How Did It Work Out For The Stocks?

New Aetna Clinical Policy Bulletin Details 'Medical Necessity' Of Sarepta's Exondys 51

Aetna Still Undecided On Coverage For Sarepta's Highly Debated Muscular Dystrophy Treatment

New Aetna Clinical Policy Bulletin Details 'Medical Necessity' Of Sarepta's Exondys 51

Aetna Still Undecided On Coverage For Sarepta's Highly Debated Muscular Dystrophy Treatment

Sarepta Shares Fall After Anthem Blue Cross Finds Issue With Eteplirsen

Sarepta's Deal With Summit Could Be More About European Eteplirsen Approval Expectations

Sarepta Shares Fall After Anthem Blue Cross Finds Issue With Eteplirsen

Sarepta's Deal With Summit Could Be More About European Eteplirsen Approval Expectations

FDA Commish Says Sarepta's DMD Study Should Be Retracted

When Will The Rally In Sarepta Therapeutics End?

Eteplirsen Recent News

Sarepta Prices Newly-Approved DMD Drug, Cowen Upgrades Stock To Outperform

2022 Will Bring New Questions For Sarepta; Jefferies Raises Price Target From $7 To $50

Jefferies Examines The Effect Of Sarepta's Drug Approval On PTC Therapeutics

Sarepta Analysts Turn Bullish After Duchenne Muscular Dystrophy Drug Eteplirsen Gets Approval

Oppenheimer Raises Sarepta's Target From $60 To $76

William Blair Sees An End To Sarepta's Regulatory Saga, Upgrades And Lifts Price Target To $88

Biotech's 'New Sweetheart': Janney Upgrades Sarepta To Buy

Sarepta's Eteplirsen Receives Accelerated FDA Approval, Shares Soar 80%

SunTrust On Sarepta Therapeutics: FDA Likely To Deny Approval For Eteplirsen

Farkas' FDA Departure Could Signal 'Imminent Decision' For Eteplirsen

JMP On Sarepta: 'We Maintain Our 10% Chance Of First-Cycle Approval For Eteplirsen'

Exclusive: Dr. Ron Farkas, Eteplirsen's Harshest Critic, Has Left The FDA

Downside Risk In Sarepta Shares Greater Than Upside Potential, Janney Says

Wedbush Bullish On Sarepta's Eteplirsen Data

Drug Trial Extension By FDA Doesn't Change Baird's Outlook On Sarepta

What's The Deal With Sarepta?

Tuesday's Top 6 Pre-Market Gainers Explained

Wedbush Upgrades Sarepta To Outperform As 'FDA Comes Up With Option C'

Why Did Sarepta Therapeutics Plunge 20%?

Sarepta Therapeutics Says FDA Will Not Complete Eteplirsen Review By PDUFA Date; Stock Surges

Strange Price Action In Sarepta Therapeutics

Sarepta Therapeutics Surges 20% On No News

Sarepta Spikes 20%, Feuerstein Says Company Can Win FDA Drug Approval